Analysts expect LifeMD to report Q3 2026 revenue of $48.80 million and an EPS loss of $0.14, with the current stock price around $2.10 trailing a consensus price target of $8.13.
The primary focus for this report is the company’s recent disclosure regarding the need to correct historical financial statements due to revenue recognition errors.
Investors are also closely monitoring the growth of the weight-management program, which reached 108,000 subscribers in Q2 following a pivot toward multi-month branded GLP-1 plans. Recent expansion of direct-dispensing agreements with Eli Lilly and a partnership with AT&T are seen as potential long-term catalysts despite current accounting headwinds.